Castle Creek Biosciences, LLC.
12
0
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
33.3%
4 terminated/withdrawn out of 12 trials
60.0%
-26.5% vs industry average
33%
4 trials in Phase 3/4
167%
10 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Role: lead
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
Role: lead
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
Role: lead
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Role: lead
Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars
Role: lead
Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia
Role: lead
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Role: lead
Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring
Role: lead
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases
Role: lead
Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles
Role: lead
Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles
Role: lead
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars
Role: lead
All 12 trials loaded